Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.

Trial Details

NCT ID

NCT06441565

Phase

PHASE2 / PHASE3

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

Fruquintinib
Fluorouracil
Oxaliplatin

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Aged between 18 and 75 years.
Histologically confirmed colorectal adenocarcinoma.
Radiologically or pathologically confirmed liver metastasis.
At least one measurable lesion (per RECIST v1.1 criteria).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →